Vanguard Group
IMGN

Vanguard Group’s Immunogen Inc IMGN Stock Holding History

Vanguard Group’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,466,950
Closed -$755M – 4531
2023
Q4 		$755M Buy
25,466,950
+984,795
+4% +$19.6M 0.02% 742
2023
Q3 		$389M Buy
24,482,155
+3,583,129
+17% +$59.6M 0.01% 1043
2023
Q2 		$394M Buy
20,899,026
+5,930,704
+40% +$70M 0.01% 1069
2023
Q1 		$57.5M Buy
14,968,322
+589,887
+4% +$2.51M ﹤0.01% 2105
2022
Q4 		$71.3M Sell
14,378,435
-1,246,413
-8% -$6.76M ﹤0.01% 1987
2022
Q3 		$74.7M Sell
15,624,848
-434,172
-3% -$2.29M ﹤0.01% 1970
2022
Q2 		$72.3M Buy
16,059,020
+580,504
+4% +$2.52M ﹤0.01% 2003
2022
Q1 		$73.7M Buy
15,478,516
+346,764
+2% +$1.92M ﹤0.01% 2106
2021
Q4 		$112M Buy
15,131,752
+520,129
+4% +$3.23M ﹤0.01% 1924
2021
Q3 		$82.8M Sell
14,611,623
-41,567
-0.3% -$240K ﹤0.01% 2083
2021
Q2 		$96.6M Buy
14,653,190
+346,051
+2% +$2.41M ﹤0.01% 2017
2021
Q1 		$116M Buy
14,307,139
+150,139
+1% +$1.23M ﹤0.01% 1871
2020
Q4 		$91.3M Sell
14,157,000
-31,530
-0.2% -$184K ﹤0.01% 1871
2020
Q3 		$51.1M Sell
14,188,530
-716,464
-5% -$2.89M ﹤0.01% 2009
2020
Q2 		$68.6M Sell
14,904,994
-1,137,790
-7% -$4.84M ﹤0.01% 1844
2020
Q1 		$54.7M Buy
16,042,784
+1,817,114
+13% +$7.94M ﹤0.01% 1833
2019
Q4 		$72.6M Buy
14,225,670
+286,114
+2% +$971K ﹤0.01% 1926
2019
Q3 		$33.7M Buy
13,939,556
+3,280,077
+31% +$8.71M ﹤0.01% 2247
2019
Q2 		$23.1M Buy
10,659,479
+130,329
+1% +$308K ﹤0.01% 2439
2019
Q1 		$28.5M Buy
10,529,150
+36,927
+0.4% +$160K ﹤0.01% 2349
2018
Q4 		$50.4M Buy
10,492,223
+333,789
+3% +$2.03M ﹤0.01% 2025
2018
Q3 		$96.2M Buy
10,158,434
+390,917
+4% +$3.76M ﹤0.01% 1824
2018
Q2 		$95M Buy
9,767,517
+878,909
+10% +$9.27M ﹤0.01% 1808
2018
Q1 		$93.5M Sell
8,888,608
-766,919
-8% -$7.58M ﹤0.01% 1753
2017
Q4 		$61.9M Buy
9,655,527
+2,376,273
+33% +$14.7M ﹤0.01% 1957
2017
Q3 		$55.7M Buy
7,279,254
+3,030,566
+71% +$20.1M ﹤0.01% 1982
2017
Q2 		$30.2M Buy
4,248,688
+138,257
+3% +$633K ﹤0.01% 2273
2017
Q1 		$15.9M Buy
4,110,431
+27,141
+0.7% +$79.2K ﹤0.01% 2543
2016
Q4 		$8.33M Sell
4,083,290
-1,813,031
-31% -$3.64M ﹤0.01% 2828
2016
Q3 		$15.8M Sell
5,896,321
-1,121,389
-16% -$3.26M ﹤0.01% 2471
2016
Q2 		$21.6M Buy
7,017,710
+309,005
+5% +$1.94M ﹤0.01% 2296
2016
Q1 		$57.2M Buy
6,708,705
+323,323
+5% +$2.74M ﹤0.01% 1806
2015
Q4 		$86.7M Buy
6,385,382
+459,957
+8% +$5.66M 0.01% 1560
2015
Q3 		$56.9M Buy
5,925,425
+201,268
+4% +$2.94M ﹤0.01% 1796
2015
Q2 		$82.3M Buy
5,724,157
+145,466
+3% +$1.6M 0.01% 1653
2015
Q1 		$49.9M Buy
5,578,691
+268,511
+5% +$1.94M ﹤0.01% 1912
2014
Q4 		$32.4M Buy
5,310,180
+135,054
+3% +$1.24M ﹤0.01% 2036
2014
Q3 		$54.8M Sell
5,175,126
-26,686
-0.5% -$302K ﹤0.01% 1746
2014
Q2 		$61.6M Sell
5,201,812
-41,733
-0.8% -$524K ﹤0.01% 1722
2014
Q1 		$78.3M Buy
5,243,545
+201,807
+4% +$3.18M 0.01% 1516
2013
Q4 		$74M Buy
5,041,738
+210,012
+4% +$3.23M 0.01% 1520
2013
Q3 		$82.2M Buy
4,831,726
+156,166
+3% +$2.75M 0.01% 1378
2013
Q2 		$77.6M Buy
+4,675,560
New +$75.8M 0.01% 1339

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Vanguard Group's IMGN Position: Q1 2024 in Review

Vanguard Group sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 25,466,950 shares — an estimated $755M sold.

Vanguard Group first reported a position in IMGN in Q2 2013 and held it in 43 quarters. The position peaked at $755M in Q4 2023. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Vanguard Group reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Vanguard Group sold 25,466,950 Immunogen Inc shares in Q1 2024, an estimated $755M.
  • Vanguard Group first reported a position in Immunogen Inc in Q2 2013 and held it in 43 quarters.
  • Vanguard Group's Immunogen Inc position peaked at $755M in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.